Drug price hikes, with­out jus­ti­fi­able new ev­i­dence of ben­e­fit — ICER analy­sis

For pa­tients, pol­i­cy­mak­ers and politi­cians drug prices in the Unit­ed States need some low­er­ing, as the sus­tain­abil­i­ty of the US health care sys­tem swings from pre­car­i­ous to pre­cip­i­tous. Pres­i­dent Trump and every pres­i­den­tial hope­ful worth their salt are cre­at­ing drug price low­er­ing mea­sures to mag­i­cal­ly cure the ills of the ex­ist­ing sys­tem, with­out curb­ing in­no­va­tion or ir­ri­tat­ing the in­dus­try in­to seek­ing refuge else­where. ICER, the de-fac­to cost-ef­fec­tive­ness watch­dog that is in­creas­ing­ly gain­ing trac­tion, on Tues­day un­veiled an analy­sis seek­ing to an­swer a fun­da­men­tal ques­tion: are these per­sis­tent drug price hikes jus­ti­fied?

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.